Fresenius Medical Care AG & Co. KGaA $FMS Position Lowered by Koss Olinger Consulting LLC

Koss Olinger Consulting LLC decreased its stake in shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 3.3% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 14,509 shares of the company’s stock after selling 491 shares during the period. Koss Olinger Consulting LLC’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $415,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the stock. Crossmark Global Holdings Inc. raised its stake in Fresenius Medical Care AG & Co. KGaA by 0.9% during the first quarter. Crossmark Global Holdings Inc. now owns 64,871 shares of the company’s stock worth $1,615,000 after acquiring an additional 584 shares during the period. Yousif Capital Management LLC raised its stake in Fresenius Medical Care AG & Co. KGaA by 6.8% during the second quarter. Yousif Capital Management LLC now owns 9,804 shares of the company’s stock worth $280,000 after acquiring an additional 625 shares during the period. Callan Capital LLC raised its stake in Fresenius Medical Care AG & Co. KGaA by 6.6% during the first quarter. Callan Capital LLC now owns 13,974 shares of the company’s stock worth $348,000 after acquiring an additional 870 shares during the period. Signet Financial Management LLC raised its stake in Fresenius Medical Care AG & Co. KGaA by 3.4% during the second quarter. Signet Financial Management LLC now owns 30,261 shares of the company’s stock worth $865,000 after acquiring an additional 992 shares during the period. Finally, Wayfinding Financial LLC acquired a new stake in Fresenius Medical Care AG & Co. KGaA during the first quarter worth about $25,000. Institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Price Performance

Shares of NYSE:FMS opened at $27.17 on Tuesday. The firm’s 50 day moving average is $25.92 and its two-hundred day moving average is $26.48. Fresenius Medical Care AG & Co. KGaA has a 52 week low of $18.94 and a 52 week high of $30.46. The firm has a market capitalization of $15.94 billion, a P/E ratio of 22.27, a PEG ratio of 0.65 and a beta of 0.92. The company has a current ratio of 1.44, a quick ratio of 1.08 and a debt-to-equity ratio of 0.44.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.50 by $0.02. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.39% and a return on equity of 6.75%. The business had revenue of $5.54 billion for the quarter, compared to analyst estimates of $5 billion. Analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 1.51 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Weiss Ratings upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Morgan Stanley restated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, August 12th. UBS Group lowered shares of Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a research note on Wednesday, October 15th. Finally, Zacks Research upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 6th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, Fresenius Medical Care AG & Co. KGaA has an average rating of “Hold” and a consensus price target of $27.80.

Fresenius Medical Care AG & Co. KGaA Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.